Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) is reporting third quarter earnings results on Wednesday 11th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.55 per share.
For the full year, analysts predict loss of $ 2.68 per share.
Stock Performance
Shares of Cyclacel Pharmaceuticals, Inc. traded up $ 0.06 or 1.81 percent on Tuesday, reaching $ 3.38 with volume of 49.60 thousand shares. Cyclacel Pharmaceuticals, Inc. has traded high as $ 3.45 and has cracked $ 3.28 on the downward trend
The closing price of $ 3.38, representing a 6.41 % increase from the 52 week low of $ 3.12 and a 83.06 % decrease over the 52 week high of $ 19.60.
The company has a market capital of $ 16.44 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Cyclacel Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 11th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cyclacel.com
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The companys oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia.
